Evidence map›Paper›PMID 34424920›Full record

ArticlePloS one2021

Patient preferences in the treatment of hemophilia A: A latent class analysis.

Axel C Mühlbacher, Andrew Sadler, Björn Lamprecht, Christin Juhnke

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Haemophilia in France: Modelisation of the Clinical Pathway for Patients.International journal of environmental research and public health · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Axel C MühlbacherHealth Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany.
Andrew SadlerHealth Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany.
Björn LamprechtRoche Pharma Aktiengesellschaft, Grenzach-Wyhlen, Germany.
Christin JuhnkeHealth Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany.ORCID 0000-0002-3949-0612

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo examine subgroup-specific treatment preferences and characteristics of patients with hemophilia A.

methodsBest-Worst Scaling (BWS) Case 3 (four attributes: application type; bleeding frequencies/year; inhibitor development risk; thromboembolic events of hemophilia A treatment risk) conducted via online survey. Respondents chose the best and the worst option of three treatment alternatives. Data were analyzed via latent class model (LCM), allowing capture of heterogeneity in the sample. Respondents were grouped into a predefined number of classes with distinct preferences.

resultsThe final dataset contained 57 respondents. LCM analysis segmented the sample into two classes with heterogeneous preferences. Preferences within each were homogeneous. For class 1, the most decisive factor was bleeding frequency/year. Respondents seemed to focus mainly on this in their choice decisions. With some distance, inhibitor development was the second most important. The remaining attributes were of far less importance for respondents in this class. Respondents in class 2 based their choice decisions primarily on inhibitor development, also followed, by some distance, the second most important attribute bleeding frequency/year. There was statistical significance (P < 0.05) between the number of annual bleedings and the probability of class membership.

conclusionsThe LCM analysis addresses heterogeneity in respondents' choice decisions, which helps to tailor treatment alternatives to individual needs. Study results support clinical and allocative decision-making and improve the quality of interpretation of clinical data.

Indexed as

Hemophilia ALatent Class AnalysisPatient PreferenceAdolescentAdultFactor VIIIFemaleHemorrhageHumansMaleMiddle AgedSurveys and QuestionnairesYoung AdultFactor VIII

Identifiers

PMID34424920
PMCPMC8382185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.